News
Sanofi in talks to sell stake in consumer health spinout
Rumours that Sanofi was in discussion with private equity groups over …
19691 items found
Sales & Marketing
Changing Faces – Board appointments September 2024
September brought numerous noteworthy appointments to boards of …
News
Roche gets FDA green light for breast cancer drug Itovebi
The FDA has given Roche its first regulatory approval for PI3K …
Digital
How to build a measurement framework to enable digital product success
Between digital therapeutics, HCP portals, and patient support …
News
Lawmaker asks FTC to probe Novo/Catalent deal
US Senator Elizabeth Warren has asked the Federal Trade Commission …
News
Starboard claims Pfizer 'threatened' former leaders
In another twist to the tale of Starboard Value's push for change at …
Oncology
Market Access
Medical start-ups must address the evolving risks of the FDA's final rule (or get left behind)
Embarking on the journey of a medical start-up is like navigating a …
R&D
LSX 2024 - James Graham, Recce Pharma
A lot of ink has been spilled about the anti-microbial resistance …
News
EVERSANA partners Oracle on pharmacovigilance platform
EVERSANA has signed an agreement with Oracle Argus Cloud to add to …
Market Access
Inflation Reduction Act proves positive boost for biosimilars
For the pharma industry, the IRA has made headlines due to it …
Digital
AI and new technologies: How the pharmaceutical industry is reinventing itself to meet ever more urgent needs
The world is changing rapidly, and the healthcare sector is no …
News
Sanofi invests €300m in Orano Med's lead-based radioligands
Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclea
Digital
Sponsored
Decoding physician prescribing behaviour: A data-driven jour...
Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
R&D
LSX 2024 - Dr Tadaaki Taniguchi
At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at Astellas Pharmaceuticals to talk a bit about the company and some r
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
BIO-Europe's 30th Anniversary Landmark Event in Stockholm
BIO-Europe™ celebrates 30 years of facilitating partnerships this Fall. In 1994, BIO-Europe launched with the mission to drive biotech innovation and
R&D
Partner Content
8th Dermatology Drug Development Summit
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
